deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT02128958

Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis

Sponsor: Can-Fite BioPharma

Conditions Hepatocellular Carcinoma
Interventions CF102 Placebo
Updated 18 times since 2017 Last updated: Sep 26, 2022 Started: Sep 30, 2014 Primary completion: Nov 27, 2017 Completion: Dec 31, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02128958, this PHASE2 trial focuses on Hepatocellular Carcinoma and remains completed. Sponsored by Can-Fite BioPharma, it has been updated 18 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jan 2018 · 11 months · monthly snapshot~Jan 2018 – ~Apr 2018 · 3 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Aug 2020 · 14 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jan 2022 · 10 months · monthly snapshot~Jan 2022 – ~Apr 2022 · 3 months · monthly snapshot~Apr 2022 – ~Nov 2022 · 7 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 13 earlier versions

  1. Nov 2022 — Dec 2022 [monthly]

    Completed PHASE2

  2. Apr 2022 — Nov 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  3. Jan 2022 — Apr 2022 [monthly]

    Active Not Recruiting PHASE2

  4. Mar 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

  5. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  6. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Aug 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  8. Jun 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Jun 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

  10. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  11. Jan 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  12. Feb 2017 — Jan 2018 [monthly]

    Recruiting PHASE2

  13. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Can-Fite BioPharma
Data source: Can-Fite BioPharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Belgrade, Serbia , Bucharest, Romania , Cluj-Napoca, Romania , Craiova, Romania , Dallas, United States , Iași, Romania , Kamenitz, Serbia , Kladovo, Serbia , Niš, Serbia and 8 more locations